DERMATA THERAPEUTICS, INC. — Key Metrics
2 years of history · ending 2022-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Expense Ratios
Working Capital Analysis
52-Week Range
Trailing Returns
ROIC vs WACC
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
—
Book Value Per Share
—
Free Cash Flow Per Share
—
Cash Per Share
—
OCF Per Share
—
Return on Equity
-119.2%
Return on Assets
-103.5%
Return on Invested Capital
-94.8%
Current Ratio
7.66
Quick Ratio
7.66
Asset Turnover
0.01
R&D / Revenue
8889.1%
SBC / Revenue
1463.4%
Working Capital
$10M
Net Current Asset Value
$-923K
Invested Capital
$6M
OCF / Net Income
0.92
FCF / Net Income
0.92
Accruals Ratio (Sloan)
-11.2%
Net Debt
$-6M
Net Debt / EBITDA
0.65
Interest Coverage
-172.25
Cash Coverage
-124.82
Tangible Common Equity
$6M
TCE / Total Assets
86.7%
NOPAT
$-8M
Cash ROIC
-109.5%
WC / Revenue
-22158.4%
Reinvestment Rate
0.0%
Asset Growth vs Revenue Growth
-279.6%
Stock Price (FY-end)
$982
Market Cap
—
P/B Ratio
—
P/TB Ratio
—
Enterprise Value
—
FCF Yield
—
Shareholder Yield
—
R&D Yield
—
Shares Variation (YoY)
—
Beta (5Y)
1.10
Cost of Equity
10.0%
52W High
$6K
52W Low
$427
Trailing Return 1Y
-73.8%
F-Score (Piotroski)
2.00
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.